Optimizing infrainguinal arm vein bypass patency with duplex ultrasound surveillance and endovascular therapy  by Armstrong, Paul A. et al.
From the Southern Association for Vascular Surgery
Optimizing infrainguinal arm vein bypass patency
with duplex ultrasound surveillance and
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Paul A. Armstrong, DO, Dennis F. Bandyk, MD, Jeffrey S. Wilson, MD, Murray L. Shames, MD,
Brad L. Johnson, MD, and Martin R. Back, MD, Tampa, Fla
Objective: Infrainguinal bypass grafting with arm vein is associated with lower patency rates compared with saphenous
vein conduits. In this study the effect of a duplex ultrasound surveillance program to enable identification and treat graft
lesions with open or endovascular repair on patency was analyzed.
Methods: Over 9 years 89 infrainguinal arm vein (26% spliced vein) bypasses were performed to treat critical lower limb
ischemia in 89 patients without adequate saphenous vein conduits. Seventy-six (85%) of the bypasses were repeat
procedures. Grafts were assessed at operation with duplex ultrasound scanning, then enrolled in a surveillance program.
Graft stenoses with peak systolic velocity greater than 300 cm/s and velocity ratio greater than 3.5, detected at duplex
ultrasound scanning, were repaired with percutaneous transluminal balloon angioplasty (PTA) if specific criteria were
met, including greater than 3 months since primary procedure, lesion length less than 2 cm, and graft diameter greater
than 3.5 mm, or with open surgical repair for early appearing or extensive graft lesions.
Results: During a mean 26-month follow-up, duplex surveillance resulted in a 48% (43 bypasses) intervention rate.
Primary patency rate was 43% at 3 years. Twenty-six (43%) of 61 lesions identified and repaired met criteria for PTA; the
remaining 35 graft lesions (stenosis, n  30; vein graft aneurysm, n  5) were surgically corrected with vein patch
angioplasty (n  15), interposition grafting (n  13), jump graft bypass (n  6), or open repair (n  1). At 3 years the
assisted primary patency rate was 91% (7 graft failures). Multiple interventions were performed in 18 (42%) revised grafts
because of metachronous (n  6) or repair site stenosis (n  12). In 18 graft interventions (PTA, n  9; surgery, n  9)
recurrent stenosis developed, and endovascular therapy was used in one third (n 6). At 3 years the stenosis-free patency
rate for PTA (48%) and surgically repaired (53%) graft lesions was similar.
Conclusions: Arm veins used in lower limb bypass procedures are prone to development of stenosis and aneurysm, lesions
easily detected with a life-long duplex ultrasound surveillance program. Excellent long-term patency (91%) was achieved
despite graft intervention being performed in nearly half of all bypasses and one third of revised grafts. Endovascular
treatment was possible in half of all graft stenosis, with outcomes similar to those with surgical repair. ( J Vasc Surg 2004;
40:724-31.)In the absence of greater saphenous vein, use of arm
veins has been advocated as an alternative conduit for
lower limb revascularization. Clinical reports have indi-
cated a range of graft patency rates from 40% to 73% at 3
years.1-5 Despite inferior patency rates compared with
infrainguinal bypass with greater saphenous vein (60%-
85% primary patency at 3-5 years), arm vein bypass is
preferred over prosthetic or cryopreserved vein grafts.5,6
The increased failure of arm veins is related to a number
of undesirable characteristics, including large caliber (ba-
silic vein), previous venipuncture trauma, phlebitis, and a
propensity for aneurysm dilation. Whether arm vein
bypasses are more susceptible than saphenous vein by-
passes to development of graft stenosis and thus neces-
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determined. The low morbidity of arm vein harvest and
the durability of the conduit reported by noted vascular
groups have encouraged surgeons to use arm veins for
lower extremity revascularization when the saphenous
vein is not available.5
Our group has advocated duplex ultrasound surveil-
lance after infrainguinal bypass to detect and repair flow-
reducing lesions and to select focal stenotic lesions for
treatment with balloon dilatation.7-11 Serial duplex as-
sessment of lower limb vein bypasses at operation, before
discharge, and at 3-month intervals thereafter enables
comment on the durability of arm vein bypass and mech-
anisms involved in bypass failure. Use of alternative vein
conduits is typically required in patients with critical limb
ischemia due to a previous failed infrainguinal bypass.
Frequently this is the last autogenous vein bypass that
can be performed. This report provides criteria for inter-
vention in arm vein bypass abnormalities detected at
duplex scanning, selecting lesions appropriate for endo-
vascular therapy, and documenting the effectiveness of
both endovascular and surgical repairs performed to
restore normal functional patency of arm vein grafts.
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 4 Armstrong et al 725METHODS
Patient demographic data. From 1994 to 2003, 89
patients (55 men, 34 women) were identified as having
undergone arm vein bypass (n  89) to treat lower limb
ischemia. This represents approximately 12% of all infrain-
guinal vein bypasses performed during this period. Demo-
graphic data for 89 patients (mean age, 71 years; range,
48-86 years) selected for arm vein bypass are shown in
Table I. All patients had critical ischemia, manifested as rest
pain alone (n  20, 22%) or ischemic ulcer or gangrene (n
 69, 78%). Seventy-six bypasses (85%) bypasses were
performed as repeat operative procedures because of a
failed infrainguinal saphenous vein (n  58) or polytetra-
fluoroethylene (PTFE; (n  18) bypass graft. Thirty-four
patients (38%) had undergone other lower limb revascular-
ization procedures, including contralateral lower limb by-
pass (n  22, 26%), aortofemoral bypass (n  13), or iliac
angioplasty (n  4).
Preoperative evaluation included lower limb arteriog-
raphy to identify suitable proximal and distal bypass anas-
tomotic sites, and upper extremity duplex vein mapping to
facilitate arm vein conduit selection based on caliber (2.5
mm), usable length (10 cm), and absence of sclerosis.
Arm veins used for bypass grafting consisted of 28 cephalic
(31%) and 38 basilic (43%) single-segment conduits, and
23 (26%) spliced basilic or cephalic arm veins. Excluded
from this analysis were arm saphenous vein and prosthetic
arm vein composite bypasses.
Arm vein bypass operative procedure. Arm vein har-
vest and exposure of the arterial inflow and outflow arteries
were typically accomplished with a 2-team approach. Ac-
cording to attending surgeon preference, 39 arm vein
conduits were implanted in reverse configuration, whereas
46 arm vein conduits were implanted nonreversed after
valve lysis with Karmody scissors, modified Mills valvu-
lotome (V. Mueller), or direct valve site exposure and
excision of leaflets. The inflow artery of the arm vein bypass
was the common femoral artery in 38 bypasses (43%), the
superficial femoral artery in 22 bypasses (25%), the deep
(profunda) femoral artery in 12 bypasses (13%), and the
popliteal artery in 17 bypasses (19%). Sixty-four bypasses
(72%) were to an infrageniculate or pedal artery (Table II).
In the absence of patient-specific contraindications,
perioperative administration of antiplatelet therapy (aspi-
Table I. Patient demographic data
Characteristic %
Men 62
Hypertension 73
Coronary artery disease (previous CABG or PTA) 55
Diabetes mellitus 53
Hyperlipidemia 51
History of smoking 85
Current tobacco smoking 27
End-stage renal disease, previous renal transplant 6
CABG, Coronary artery bypass graft; PTA, percutaneous transluminal an-
gioplasty.rin, clopidogrel), dextran-40 (25 mL/hr for 24 hours), and
low molecular weight heparin (30 mg subcutaneously twice
a day) was routinely used. Approximately one third of
patients were discharged with oral anticoagulation therapy
(warfarin sodium [Coumadin]) with an international nor-
malized ratio target value of 1.5 to 2 unless specific indica-
tions for therapeutic anticoagulation (international nor-
malized ratio, 2-3.5) existed, such as atrial fibrillation,
known hypercoagulable condition, repeat vein bypass, or
graft flow velocity less than 45 cm/s. All patients were
prescribed long-term antiplatelet therapy, that is, aspirin
(325 mg/d) or clopidogrel (75 mg/d).
Intraoperative duplex ultrasound assessment. The
arm vein bypass was evaluated with color duplex ultrasound
scanning after restoration of flow and verification of a
functioning bypass at visual inspection and pulse palpation.
The previously described technique of papaverine-
augmented duplex scanning was used,10,11 and consisted of
intragraft injection of papaverine hydrochloride (30-60
mg) through a 27-gauge needle to augment graft flow and
vasodilate the runoff arterial bed. The entire arterial recon-
struction was then imaged, beginning at the distal anasto-
mosis and proceeding through the proximal anastomotic
region, including the exposed inflow artery, anastomotic
sites, venovenostomies, and any graft region where real-
time color Doppler scans demonstrated lumen reduction or
disturbed flow pattern. At sites of duplex-detected stenosis,
measurements of peak systolic velocity (PSV) were made
and the velocity ratio (Vr) was calculated, where Vr PSV
at lesion/PSV proximal to lesion. Graft and anastomotic
abnormalities with PSV greater than 150 to 200 cm/s and
Vr greater than 2 were revised.
Postoperative duplex ultrasound surveillance
protocol. All patients were enrolled in a graft surveillance
protocol, which included clinical evaluation for recurrent
limb ischemia, measurement of Doppler-derived ankle sys-
tolic pressure (ankle-brachial index), and color duplex scan-
ning.11 Graft surveillance was performed before discharge
from the hospital, 3 to 4 weeks later in an outpatient
laboratory accredited by the Intersocietal Commission for
Accreditation of Vascular Laboratories, subsequently every
3 months for the first 2 years after bypass grafting, and then
every 6 months. The interval between duplex scanning was
reduced in selected patients, because of changes in the limb
Table II. Anatomic configuration of 89 infrainguinal
arm vein bypasses
Bypass, configuration
No. of
grafts
Femoropopliteal, above knee 6
Femoropopliteal, below knee 18
Femoral, anterior tibial 23
Femoral, posterior tibial 7
Femoral, peroneal 15
Femoral, dorsalis pedis 3
Popliteal, tibial 12
Popliteal, pedal 5
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sion of an identified stenosis. At each surveillance visit the
entire vein bypass graft was scanned, including the inflow
and distal native arteries. Measurements of PSV from nor-
mal vein segments in the proximal, midgraft, and distal
graft were recorded to detect development of “low” (mean
PSV decrease 30 cm/s compared with previous study or
level of45 cm/s) graft flow velocity. When a graft steno-
sis was identified, measurements of PSV and Vr at the
stenosis were recorded. The criteria for recommending
repair of a duplex scan–detected stenosis included PSV
greater than 300 cm/s and Vr greater than 3.5.11,12 If no
stenosis was identified in a graft in which low flow velocity
developed or ankle-brachial index decreased, angiography
was recommended. Vein graft aneurysms were diagnosed
on the basis of real-time B-mode and color Doppler imag-
ing by greater than 2-fold focal enlargement of the vein
graft and the presence of mural thrombus. The duplex
criteria for repeat intervention to treat a repair site stenosis
was identical to primary graft stenosis, that is, PSV greater
than 300 cm/s and Vr greater than 3.5.
Interventions to treat duplex scan–detected graft
stenosis or aneurysm. Stenotic graft lesions were cor-
rected with either endovascular (percutaneous transluminal
balloon angioplasty; PTA) or open surgical repair. The
method used depended on specific criteria, including time
since procedure, lesion length, and vein graft diameter. A
graft stenosis was considered for PTA if the interval from
the initial bypass procedure was greater than 3 months,
duplex scans indicated a stenosis length of 2 cm or less, and
the adjacent uninvolved vein graft had a diameter of at least
3.5 mm. Surgical intervention was selected to repair or
replace stenotic graft segments in which small-caliber
(3.5 mm) vein grafts developed; to treat residual graft
stenosis, myointimal lesions that developed within 3
months of bypass grafting, long (2 cm) or diffuse vein
graft stricture, residual stenosis after PTA, or recurrent
stenosis developing within 2 months of successful PTA; and
for recurrent stenotic open surgical repairs. The type of
surgical intervention varied with graft abnormality identi-
fied: stenosis (vein patch angioplasty, interposition graft-
ing, jump graft) or vein graft aneurysm (interposition vein,
PTFE grafting). Intraprocedural duplex scanning was per-
formed after PTA and surgical interventions to verify cor-
rection of the stenosis, based on color duplex criteria of
widely patent lumen, PSV less than 180 cm/s, and Vr less
than 2 at the repair site.
Data analysis. Adverse patient outcome, including
death, graft thrombosis, graft revision, and amputation,
was recorded throughout follow-up. Only 3 patients were
lost to follow-up, all after 1 year of the primary grafting
procedure. Life table estimates of primary graft patency and
assisted primary graft patency were determined according
to accepted reporting guidelines.13 Differences between
groups were compared with 2 analysis and log-rank test,
with P  .05 considered significant.RESULTS
Thirty-day outcomes. One patient died after femo-
roperoneal arm vein bypass to treat ischemic ulcer, as a
result of myocardial infarction (1% procedural mortality).
The intraoperative duplex scan was interpreted as normal in
72 (81%) arm vein bypasses. Immediate revision was per-
formed in 17 grafts with an abnormal intraoperative scan,
and all patients left the operating room with a successful
bypass graft based on duplex scan criteria. In 1 patient an
abnormal predischarge graft scan demonstrated a technical
error (incomplete valve lysis), which prompted open repair
with repeat introduction of a valvulotome. All bypasses
were patent at patient discharge from the hospital and at 30
days. Duplex scans at the first outpatient visit demonstrated
no graft abnormality in 74 of 88 (84%) arm vein bypasses.
Outcomes after 30 days. Eleven patients died during
follow-up, with 4 deaths during the first 3 years due to
cardiovascular events (n  3) or burn trauma (n  1);
patient survival at 3 years was 88%. Despite duplex surveil-
lance and repair of identified graft lesions, graft thrombosis
(femoropopliteal, n  1; femorotibial, n  7; popliteal-
pedal, n  1) occurred in 9 patients. A graft abnormality
(stenosis, n  5; aneurysm, n  1) was identified and or
recently repaired in 6 patients. In 2 patients the graft was
salvaged with catheter-directed thrombolysis followed by
surgical repair of a known graft stenosis or vein aneurysm.
During a mean follow-up of 26 months, 7 arm vein by-
passes failed, for a cumulative assisted graft patency of 91%
at 3 years (Table III). Failed grafts included 3 spliced, 2
cephalic, and 2 basilic arm vein conduits. Five patients
required limb amputation (above knee, n 1; below knee,
n  4) after graft failure; 1 patient died before repeat
intervention could be performed; and in 1 patient an isch-
emic leg wound healed, but the patient was lost to
follow-up 11 months later. Two of the 5 amputations
occurred within 6 months (2, 3, 6, 51, and 78 months,
respectively) of arm vein bypass grafting, and in 3 patients 4
secondary procedures (surgical repair, n  3; PTA, n  1)
had been performed because of graft stenosis. Overall,
cumulative limb salvage was 97% at 3 years.
A total of 632 postoperative scans (average, 7 scans per
patient) were obtained in the study population. Duplex
surveillance identified development of graft abnormalities
in 48 of 88 bypasses (55%), of which 5 have not been
repaired and are being observed, and 43 patients (49%)
underwent an intervention to repair stenosis (n  38) or
vein graft aneurysm (n  5). Four of 5 graft aneurysms
developed in a basilic vein conduit. The intervention-free
(primary) patency rate was 68% at 1 year, and 43% at 3
years, by life table analysis (Fig 1; Table IV). The interven-
tion rate was higher (P  .01) for spliced vein bypasses
(83%; 19 of 23) than for single-segment cephalic vein
bypasses (44%; 12 of 27) or basilic vein bypasses (32%; 12 of
38). The revision rate was similar for reversed (44%) and
nonreversed (56%) arm vein conduits.
Sixty-one graft abnormalities were identified and re-
paired, including 56 graft stenosis (32 primary, 6 meta-
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interval from grafting procedure to repair of a primary graft
stenosis was 14  19 months (range, 1-76 months; me-
dian, 5 months), and for vein graft aneurysm was 18
months (range, 6-47 months; Fig 2). No grafts were lost
from wound complications or infection. The site of re-
paired graft abnormality involved the proximal anastomosis
in 22% of bypasses, mid-graft anastomosis in 43% of by-
passes, and distal anastomosis in 35% of bypasses. Twenty
(53%) of 38 primary or metachronous graft stenoses were
treated with PTA. In 5 patients duplex-monitored PTA
resulted in repeat balloon dilation based on persistent ele-
vated PSV at the angioplasty, despite an angiogram show-
ing no residual stenosis. The remaining 23 graft lesions
(stenosis, n 18; aneurysm, n 5) were repaired surgically
with vein patch angioplasty (n  10), vein interposition (n
Fig 1. Life table analysis of primary, assisted primary,
bypasses.
Table III. Cumulative assisted primary patency of 89 infr
Interval (mo)
No. of
grafts at risk
No. of
grafts
revised g
1 89 7
3 88 7
6 86 4
9 82 2
12 75 1
15 71 2
18 63 1
21 60
24 56 2
27 49
30 45
33 44 2
36 43 1 5), jump graft bypass (n  5), PTFE graft interposition
(n  2), or valve lysis (n  1). Repair of duplex scan–
detected graft problems resulted in a primary graft patency
rate of 68% at 1 year and 43% at 3 years (Fig 1; Table IV).
Recurrent stenosis developed in 18 revised grafts (42%)
after PTA (9 of 20) or surgical repair (9 of 23) at a mean
interval of 8 10 months (range, 1-40 months; median, 6
months). No graft required revision because of “new” vein
graft aneursym development. Endovascular intervention
was performed on the basis of duplex scanning selection
criteria at 6 of 18 recurrently stenotic graft sites. Three
grafts required multiple revisions because of recurrent ste-
nosis at the repair site. For the 61 graft interventions (PTA,
n  26, surgery, n  35) the stenosis-free (primary) pa-
tency of PTA and surgical repair was similar at 1 year (48%
and 52%, respectively; P  .2). At the last follow-up, 65
secondary patency rates for 88 infrainguinal arm vein
inal arm vein bypasses at life table analysis
. of
failed
No. of
grafts
withdrawn
Interval
patency
Cumulative
patency
1 100 100
0 98 98
0 95 93
7 100 93
4 100 93
8 100 93
3 98 91
3 100 91
7 100 91
4 100 91
1 100 91
1 100 91
3 100 91andaingu
No
rafts
2
4
1
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served. Six grafts have a duplex scan–identified stenosis
(PSV  180 cm/s), and these lesions are being monitored
for progression. Of note, the use of warfarin sodium anti-
coagulation therapy in one third of patients has not been
associated with any differences in primary or assisted graft
patency rates.
DISCUSSION
Our experience with arm veins for use in lower limb
bypass grafting has confirmed clinical applicability and du-
rability of these autogenous conduits for treatment of crit-
ical limb ischemia. Duplex surveillance demonstrated that
the arm vein conduits were prone to development of both
stenotic and aneurysmal lesions. Nearly half of the bypasses
required a corrective intervention, the most common prob-
lem being development of conduit stenosis within 9
Fig 2. Time to repair of 32 primary and 6 metachrono
(PTA) or surgery, and of 5 identified vein graft aneurysm
Table IV. Cumulative primary patency of 89 infrainguina
Interval
(mo)
No. of
grafts at risk
No. of
grafts
revised
1 89 7
3 81 7
6 72 4
9 64 2
12 55 1
15 50 2
18 40 1
21 35
24 32 2
27 23
30 19
33 18 2
36 15 1months of the procedure. Percutaneous transluminal bal-
loon dilation was selected to treat 53% of primary graft
stenoses and 33% of recurrent graft stenoses, on the basis of
clinical and duplex scanning criteria for endovascular inter-
vention.9 Duplex ultrasound scanning was clinically useful
both during and after operation by enabling detection of
both residual and acquired (nontechnical) graft problems.
Vascular laboratory surveillance after operation led to repair
of 61 graft abnormalities, resulting in a 43% primary pa-
tency rate at 3 years, but assisted graft patency rate (91%)
and limb salvage rate (97%) were excellent. Spliced arm vein
bypasses had the highest (83%) intervention rate. Graft
failure occurred in 7 patients, and was related to progres-
sion of a known graft problem in 3 instances. Of note, no
patient died as a result of graft repeat intervention, and
patient survival at 3 years was 88%, despite typical athero-
sclerotic risk factors associated with critical limb ischemia
aft stenosis with percutaneous transluminal angioplasty
th interposition grafting.
vein bypasses at life table analysis
No. of
grafts
withdrawn
Interval
patency
Cumulative
patency
1 92 92
0 88 81
0 88 71
7 97 69
4 98 68
8 95 64
3 94 61
3 100 61
7 92 56
4 100 56
1 100 56
1 86 48
3 90 43us gr
s wil arm
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larization.
Although arm vein harvest requires increased operative
effort and vein conduit splicing or repair is required in a
significant number of patients to achieve sufficient vein bypass
quality and length, there will be healing of ischemic lesions,
limb salvage, and a relatively durable bypass graft. Modern
reports of this alternative vein bypass state that expected 3-year
secondary patency rate is in the range of 70%.1-5 Caveats to
using arm veins successfully have included operative assess-
ment of vein quality and technical precision in bypass con-
struction. Whereas angioscopy has been championed at oper-
ation to enable identification of unsuspected vein graft lesions,
we believe duplex ultrasound scanning has appropriate sensi-
tivity to enable identification of technical problems that
threaten early patency.4,5 Postoperative surveillance has also
been recommended, but a recent report on arm vein bypass
patency cited similar 1-year and 3-year primary (80% and 69%,
respectively) and secondary (81% and 70%, respectively) graft
patency rates, which indicates that the yield of the surveillance
protocol was minimal.5 We found that duplex surveillance
enables identification of a graft problem in 20% to 40% of
patients, and repair of these lesions accounts for the significant
difference in primary and secondary patency rates.2
To achieve an all-autogenous approach to infrainguinal
revascularization, use of arm veins is necessary. We have
performed arm vein bypasses only to treat critical limb
ischemia, and most patients (85%), as might be expected,
had received a previous infrainguinal bypass that failed.
Despite previous graft failure and bypass to the infragenicu-
late or pedal artery in more than 70% of patients, successful
bypass can be expected when the intraoperative papaverine-
augmented duplex scan confirms no graft lesion and a low
resistance blood flow pattern in the distal graft and outflow
artery. Inasmuch as arm vein bypass is a technically de-
manding procedure, we recommend predischarge duplex
ultrasound assessment to confirm normal functional pa-
tency. Problems related to valve lysis, graft tunneling, and
vein-vein anastomosis can be identified and corrected. This
approach contributed to the high graft patency rate (100%)
documented at discharge. Duplex scanning is also useful in
documenting the technical success of graft interventions,
especially endovascular therapy. Our group has reported
that residual stenosis can be present in one fifth of PTA
sites, despite a completion angiogram that shows no resid-
ual stenosis.14 Use of PTA to treat myointimal vein graft
lesions may be controversial, but our accumulated experi-
ence indicates that similar results can be achieved in either
arm or saphenous vein bypasses if specific selection criteria
are used.9,14,15 Duplex surveillance after both endovascular
and surgical intervention is important, because recurrent
stenosis can develop in as many as 40% of revision sites. The
nature of the graft lesions that develop in arm vein bypasses
are time-dependent; half of stenotic lesions develop within
6 months after implantation into the arterial circulation,
whereas aneurysmal degeneration of the arm vein conduit
occurs later. Diffuse aneurysmal dilatation of arm vein
bypass has been reported, especially in patients with popli-teal aneurysm disease, but this graft problem was not
observed in our study.1 Focal vein graft aneurysm with
mural thrombus was identified in 5 bypasses at 6 to 47
months after the procedure. Treatment with autogenous
vein interposition is recommended. In several patients
without adequate autogenous vein we have had to resort to
use of short-segment PTFE interposition grafts. The pro-
pensity of arm vein bypasses for development of stenosis
and aneurysms suggests that lifelong duplex surveillance is
necessary, with more frequent testing during the first 6
months after operation. If a moderate graft stenosis (150
cm/s  PSV 300 cm/s, Vr 3.4) is detected, the testing
interval should be shortened to 6 to 8 weeks, because these
lesions can demonstrate unpredictable progression. When
duplex scans indicate stenosis progression the patient
should be counseled that repair of the graft abnormality is
safe and prevents graft failure. The data from this retrospec-
tive study are useful in documenting the natural history of
arm vein bypasses observed in a rigorous duplex surveil-
lance protocol. Patient outcomes were similar to those in
other reports, and support the use of these alternative
autogenous veins for treatment of critical limb ischemia.2,5
When available, the basilic vein may be the preferred arm
vein conduit, because the need for intervention is the low-
est.16 The role of endovascular therapy of acquired graft
stenosis should be studied further, but patients definitely
prefer this less invasive method for repair of a stenotic vein
segment. When arm vein bypass is performed, the patient and
the referring physician should be made aware that this is
probably the last autogenous bypass that can be performed.
The patient has the responsibility to control the risk factors for
atherosclerotic disease, working in conjunction with the pri-
mary care physician; and the treating vascular surgeon should
ensure that duplex surveillance is available and performed,
antiplatelet therapy is prescribed, and identified graft abnor-
malities are corrected in a timely fashion.
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Submitted Jan 13, 2004; accepted Jul 21, 2004.DISCUSSIONDr Spence M. Taylor (Greenville, SC). It is a real honor to be
asked to open the discussion of this paper by Drs Armstrong,
Bandyk, and others regarding the optimization of arm vein bypass
patency using duplex ultrasound surveillance. While most of the
members of our society are aware of Dr Bandyk’s contribution to
vascular surgery in regard to graft surveillance, there may be some
younger members, fellows, residents, and medical students who
are not. Dr Bandyk’s name, in many respects, has become synon-
ymous with duplex scan graft surveillance. His described tech-
niques using the scanner have become an ingrained standard in the
practice of vascular surgery. Few in this room have contributed to
our field in such a way as to affect the daily management of patients
the way that Dr Bandyk has. So, at the start, let me congratulate Dr
Bandyk for his contribution.
At first glance this paper appears to be another study on the
much reported topic of arm vein infrainguinal bypass. However, on
closer inspection this study has a great deal of new information, and
I recommend the manuscript to everyone. Again, any paper on
duplex ultrasound surveillance for infrainguinal bypass from Dr
Bandyk’s group should be weighed accordingly.
We have just heard several interesting and sobering statistics
presented in this study. During a mean follow-up of 2 years nearly
half of the bypass grafts in this series developed graft-threatening
lesions requiring intervention, and subsets such as spliced vein
conduits developed graft-threatening lesions in 85% of grafts. Half
of the revised grafts required re-revision over time, regardless of
the original technique used to revise the first vein graft stenosis—
PTA or open surgery.
While the 3-year assisted primary patency rate of 91% for the
entire series is impressive, the energy and cost to achieve such
results was tremendous. These grafts had a 3-year primary patency
rate of only 43%, testifying to the extensive surveillance protocol
required to achieve these results, including technically challenging
and expensive intraoperative duplex scanning and often painful
immediate postoperative scanning in all patients. There were a
mean number of 7 scans per graft at 2 years. This is at the root of
my first question. Can the average vascular surgeon practicing in
several different hospitals on a daily basis expect to have the
consistent technical support and resources (ie, vascular lab support
and know-how) to achieve acceptable results for arm vein bypass?
If the answer is no, then what is the role of arm vein bypass to most
practicing vascular surgeons? A primary failure of more than 50% at
3 years may be deemed prohibitive by most. What are your
thoughts?
Second, I was struck by the lack of any opinion expressed in
your manuscript regarding the routine use of arm vein conduits. Is
this a positive or negative study? Arm vein, in your experience, was
very high maintenance. You had almost as many revisions as you
did original bypasses (55 vs 85). Is all this really worth it? Should
we be doing something else? The ultimate patency results are
outstanding, but what about the functional results? What do yourpatients think? From their perspective, it must be troubling to
think that every time they go see Dr Bandyk in the office they have
a 50% chance of being told they need another operation. In
Greenville, my patients would probably seek care elsewhere. What
are your thoughts?
Dr Paul Armstrong. In regard to whether you think com-
munity surgeons can perform arm vein bypass and surveillance, this
is exactly the perspective I had before I reentered fellowship. It
certainly takes quite a bit of dedication. Not only is it necessary for
the vascular lab to call the patients to remind them of their
surveillance, but it also takes your partners to come in and fix these
problems after hours, because, as we all know, that is traditionally
when most of these veins tend to go down or develop trouble.
When you go out in the community, as I did, I think one of the
things I learned rather quickly is that I can’t do everything I
learned in residency, so maybe these sorts of bypasses ought to be
referred to a tertiary center.
Whether it is worth it or not I believe depends on patient
satisfaction. We keep getting these folks back, and they keep
signing the operative consent, so I guess they feel that limb salvage
is worth it.
Dr Blair Keagy (Chapel Hill, NC). I have 3 questions.
First, obviously the spliced veins didn’t do so well as the other
veins did, and if you can take a single vein or sometimes both the
cephalic and the basilica veins and use a crossover vein in the
antecubital fossa, that’s great. But what do you regard as a spliced
vein? One anastomosis? Two anastomoses? I have seen some papers
in which if they use 2 or more anastomoses to put arm veins
together the results are about the same as with prosthetic material.
The second question is in regard to the lesser saphenous vein
and where that fits in with relation to the arm vein.
And third, with regard to your preoperative mapping, do you
go on the basis of diameter, and, if so, what’s the diameter that’s
necessary to qualify as an acceptable arm vein?
Dr Armstrong. For the purpose of this paper we describe
anything spliced as being 2 or more anastomoses.
In terms of the lesser saphenous, we really don’t use that vein
too often. We like to use a vein graft diameter that is 2.5 mm or
greater.
Dr James Seeger (Gainesville, Fla). One comment about
these things being a lot of trouble: they are. There is no question
about that, so you probably are going to reserve such bypasses for
patients who are either going to have no leg or are going to have
one of these bypasses that is a lot of trouble. That is because there
is no other option as, at least in our experience, use of either a
cadaveric vein graft or prosthetic grafts with vein cuffs, which I am
not convinced is anything more than smoke and mirrors, in such
patients is disastrous.
My questions are these. First, the use of spliced arm veins really
means that you don’t have good arm vein. Did you use angioscopy
to assess these veins, because Frank LoGerfo’s group would say
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them, and I think that’s probably our experience, as well.
Second, one of the things that we found on follow-up graft
scans, particularly when large basilic veins have been used, is
that we commonly get these significantly elevated graft velocity
ratios at the anastomosis, where it goes from a 6-mm basilic vein
to a 1-mm peroneal artery. I’d be interested in your comments.
Dr Armstrong. In terms of angioscopy, it is a diagnostic
method that we don’t use often, but its utility is well established in
the literature. We advocate the use of complete intraoperative
duplex scanning of the entire graft length for evaluation of thebypass graft and outflow tract.
I didn’t mean to give the impression that we don’t look at the
anastomoses or that problems don’t occur there, because they do.
In this series about 43% of duplex abnormalities actually occurred
in the midportion of the graft. The remainder of the abnormal
duplex scans involved the regions of anastomosis or the outflow
tract. We use a papaverine-augmented intraoperative duplex scan
intraoperatively to augment flow in the outflow tract. We intraop-
eratively revise residual lesions if they demonstrate a peak sys-
tolic velocity greater than 150 cm/s or a velocity ratio greater
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